117 related articles for article (PubMed ID: 33169580)
1. [Construction of CAR-T cells targeting CS1 and analysis of their antitumor activity in vitro].
Zhang W; Wang C; Tao Z; Yin C; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):2162-2170. PubMed ID: 33169580
[TBL] [Abstract][Full Text] [Related]
2. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].
Feng DD; Chen XH; Guo JJ; Wang KK; Zhang XM; Gao JM
Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):657-665. PubMed ID: 34289557
[No Abstract] [Full Text] [Related]
4. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.
Chu J; He S; Deng Y; Zhang J; Peng Y; Hughes T; Yi L; Kwon CH; Wang QE; Devine SM; He X; Bai XF; Hofmeister CC; Yu J
Clin Cancer Res; 2014 Aug; 20(15):3989-4000. PubMed ID: 24677374
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
[No Abstract] [Full Text] [Related]
6. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
Chu J; Deng Y; Benson DM; He S; Hughes T; Zhang J; Peng Y; Mao H; Yi L; Ghoshal K; He X; Devine SM; Zhang X; Caligiuri MA; Hofmeister CC; Yu J
Leukemia; 2014 Apr; 28(4):917-27. PubMed ID: 24067492
[TBL] [Abstract][Full Text] [Related]
7. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells.
O'Neal J; Ritchey JK; Cooper ML; Niswonger J; Sofía González L; Street E; Rettig MP; Gladney SW; Gehrs L; Abboud R; Prior JL; Haas GJ; Jayasinghe RG; Ding L; Ghobadi A; Vij R; DiPersio JF
Leukemia; 2022 Jun; 36(6):1625-1634. PubMed ID: 35422095
[TBL] [Abstract][Full Text] [Related]
8. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
9. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis.
Rosenzweig M; Urak R; Walter M; Lim L; Sanchez JF; Krishnan A; Forman S; Wang X
Cytotherapy; 2017 Jul; 19(7):861-866. PubMed ID: 28483281
[TBL] [Abstract][Full Text] [Related]
10. [Eukaryotic expression, protein purification and biological effects research of human CS1-Fc fusion protein].
Chen R; Wang X; Li Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 Jan; 36(1):122-132. PubMed ID: 32072787
[TBL] [Abstract][Full Text] [Related]
11. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
12. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.
Golubovskaya V; Zhou H; Li F; Berahovich R; Sun J; Valentine M; Xu S; Harto H; Sienkiewicz J; Huang Y; Wu L
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680541
[TBL] [Abstract][Full Text] [Related]
13. T cells engineered with full-length NKG2D linked to signaling domains of 4-1BB and CD3ζ show enhanced antitumor activity.
Teng X; Rong Z; Li S; Yang W; Lu Z
Immunol Cell Biol; 2023 May; 101(5):458-464. PubMed ID: 36811384
[TBL] [Abstract][Full Text] [Related]
14. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
[TBL] [Abstract][Full Text] [Related]
15. A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.
Chan WK; Kang S; Youssef Y; Glankler EN; Barrett ER; Carter AM; Ahmed EH; Prasad A; Chen L; Zhang J; Benson DM; Caligiuri MA; Yu J
Cancer Immunol Res; 2018 Jul; 6(7):776-787. PubMed ID: 29769244
[TBL] [Abstract][Full Text] [Related]
16. A compound chimeric antigen receptor strategy for targeting multiple myeloma.
Chen KH; Wada M; Pinz KG; Liu H; Shuai X; Chen X; Yan LE; Petrov JC; Salman H; Senzel L; Leung ELH; Jiang X; Ma Y
Leukemia; 2018 Feb; 32(2):402-412. PubMed ID: 28951562
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract][Full Text] [Related]
18. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
Metzger TC; Long H; Potluri S; Pertel T; Bailey-Bucktrout SL; Lin JC; Fu T; Sharma P; Allison JP; Feldman RM
Cancer Res; 2016 Jul; 76(13):3684-9. PubMed ID: 27197182
[TBL] [Abstract][Full Text] [Related]
19. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
20. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
[No Abstract] [Full Text] [Related]
[Next] [New Search]